Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Telaprevir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 13/20 | 1.00 |
| ▸ | CTSL | P07711 | 8/20 | 1.00 |
| ▸ | CTSK | P43235 | 6/20 | 1.00 |
| ▸ | CTSS | P25774 | 3/20 | 1.00 |
| ▸ | ELANE | P08246 | 2/20 | 1.00 |
| ▸ | CTSV | O60911 | 1/20 | 1.00 |
| ▸ | PLG | P00747 | 1/20 | 1.00 |
| ▸ | CMA1 | P23946 | 1/20 | 1.00 |
| ▸ | CELA1 | Q9UNI1 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.90 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Telaprevir SCHEMBL13201989 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL19204685 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL13201896 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL13201998 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL13201906 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL13219429 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL15847464 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL13201929 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL22171584 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL22171583 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360783-A1 | Methods for Treating HCV | ABBVIE INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170360783-A1 | Methods for Treating HCV | ABBVIE INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20110195912-A1 | Oligomer-Protease Inhibitor Conjugates | NEKTAR THERAPEUTICS (US) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360783-A1 | Methods for Treating HCV | EIF2AK2, IFNG, IFNAR1 | CTSB 359/4885CTSL 318/4885CTSK 627/4885 |
| US-20110195912-A1 | Oligomer-Protease Inhibitor Conjugates | DNPEP, SERPINB1, MME | CTSB 26/4885CTSL 61/4885CTSK 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.